[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337379-105":59,"doc-detail-337379-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-immune-checkpoint-tigitcd155-promotes-the-exhaustion-of-cd8-t-cells-in-tnbc-through-glucose-metabolic-reprogramming-mediated-by-pi3kaktmtor-signaling","The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling","","Objective: The CD155/TIGIT axis is studied as an emerging immune checkpoint with potential cancer immunotherapy applications. The research investigates how CD155/TIGIT checkpoints contribute to triple-negative breast cancer (TNBC) progression. Methods: CD155 and TIGIT expression in TNBC tissues was assessed using immunohistochemistry and gene expression profiling, supported by in vivo and in vitro functional experiments. Results: CD155 is upregulated with a negative association to CD8 + T-cell infiltration, while TIGIT is elevated; the interaction suppresses PI3K/AKT/mTOR signaling, disrupting glucose metabolism and reducing cytokine production. Conclusion: Blocking CD155/TIGIT, including TIGIT antibody treatment, restores CD8 + T-cell cytokine generation and supports anti-tumor activity, suggesting a therapeutic target for TNBC.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-immune-checkpoint-tigitcd155-promotes-the-exhaustion-of-cd8-t-cells-in-tnbc-through-glucose-metabolic-reprogramming-mediated-by-pi3kaktmtor-signaling/337379/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-immune-checkpoint-tigitcd155-promotes-the-exhaustion-of-cd8-t-cells-in-tnbc-through-glucose-metabolic-reprogramming-mediated-by-pi3kaktmtor-signaling/337379.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of this study on TIGIT/CD155 in TNBC?","Question",{"text":112,"@type":113},"The study aims to determine the role of the CD155/TIGIT immune checkpoint axis in TNBC progression and its impact on immune cell function.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were CD155 and TIGIT assessed in TNBC tissues and models?",{"text":117,"@type":113},"CD155 and TIGIT expression in TNBC tissues was evaluated using immunohistochemistry and gene expression profiling, with both in vivo and in vitro experiments to test functional effects.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism links CD155/TIGIT interaction to CD8 + T-cell exhaustion?",{"text":121,"@type":113},"The interaction disrupts CD8 + T-cell glucose metabolism by suppressing PI3K/AKT/mTOR signaling, resulting in reduced cytokine production and impaired CD8 + T-cell function.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337379,1790929261,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Huang et al. Cell Communication  \nCehtltlpCsmunoi oricgtion10 11and86/Sis1g2li4n-g023-01(2024554-z) 22:35 and Signaling  \n RESEARCH Open Access  \nThe immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 +T  \ncells inTNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling  \nMingyao Huang1†, Xiaoqin Yu2†, Qing Wang1, Zirong Jiang3, Xiaofen Li1, Wei Chen4 and Chuangui Song1,2*  \nAbstract  \nObjective The CD155/TIGIT axis has attracted considerable interest as an emerging immune checkpoint with potential applications in cancer immunotherapy. Our research focused on investigating the role of CD155/TIGIT checkpointsin the progression of triple-negative breast cancer (TNBC) .  \nMethods We evaluated CD155 and TIGIT expression inTNBC tissues using both immunohistochemistry (IHC) and gene expression profiling. Our experiments, both in vivo and in vitro, provided evidence that inhibiting the CD155/TIGIT pathway reinstates the ability of CD8 + T cells to generate cytokines. To assess the impact of CD155/ TIGIT signaling blockade, we utilized Glucose Assay Kits and Lactate Assay Kits to measure alterations in glucose and lactate levels within CD8 + T cells. We employed western blotting (WB) to investigate alterations in glycolyticrelated proteins within the PI3K/AKT/mTOR pathways following the inhibition of CD155/TIGIT signaling.  \nResults CD155 exhibits heightened expression within TNBC tissues and exhibits a negative correlation  \nwith the extent of infiltrating CD8 + T cells. Furthermore, patients with TNBC demonstrate elevated levels ofTIGIT expression. Our findings indicate that the interaction between CD155 and TIGIT disrupts the glucose metabo  \nlism of CD8 + T cells by suppressing the activation of the PI3K/AKT/mTOR signaling pathway, ultimately leading to the reduced production of cytokines by CD8 + T cells. Both in vivo and in vitro experiments have conclusively demonstrated that the inhibition of CD155/TIGIT interaction reinstates the capacity of CD8 + T cells to generate cytokines. Moreover, in vivo administration of the blocking antibody against TIGIT not only inhibits tumor growth but also augments the functionality of CD8 + T lymphocytes.  \nConclusions Our research findings strongly suggest that CD155/TIGIT represents a promising therapeutic target for treating TNBC.  \nKeywords Immune checkpoint, CD155/TIGIT, CD8 +T cells, TNBC, Immunotherapy  \n†Mingyao Huang and Xiaoqin Yu contributed equally to this work.  \n*Correspondence: Chuangui Song [Songcg1971@outlook.com](Songcg1971@outlook.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[. The Creative Commons Public Domain Dedication waiver (](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[http://creativecom](http://creativecom)[mons.org/publicdomain/zero/1.0/](mons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data.  \nHuang et ","cbCain0pkUiUpqav","https://ap.wps.com/l/cbCain0pkUiUpqav","pdf",8062426,16,"English","# Abstract\n# Introduction\n## TNBC and immune checkpoint therapy\n## TIGIT and CD155 biology\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What is the main objective of this study on TIGIT/CD155 in TNBC?\",\"answer\":\"The study aims to determine the role of the CD155/TIGIT immune checkpoint axis in TNBC progression and its impact on immune cell function.\"},{\"question\":\"How were CD155 and TIGIT assessed in TNBC tissues and models?\",\"answer\":\"CD155 and TIGIT expression in TNBC tissues was evaluated using immunohistochemistry and gene expression profiling, with both in vivo and in vitro experiments to test functional effects.\"},{\"question\":\"What mechanism links CD155/TIGIT interaction to CD8 + T-cell exhaustion?\",\"answer\":\"The interaction disrupts CD8 + T-cell glucose metabolism by suppressing PI3K/AKT/mTOR signaling, resulting in reduced cytokine production and impaired CD8 + T-cell function.\"}]","The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling | PDF",1790018903,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c3f1787338521fd7b91dc6938c970ae.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5cafb4d4fcd32a58c2ebda066423dc04.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/84989b6b50487cbdaef11d169fc8249c.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a4ee30ca6fcb5ed1743683dd7019b23.webp",980,1301]